Morpholino-mediated Increase in Soluble Flt-1 Expression Results in Decreased Ocular and Tumor Neovascularization
Overview
Affiliations
Background: Angiogenesis is a key process in several ocular disorders and cancers. Soluble Flt-1 is an alternatively spliced form of the Flt-1 gene that retains the ligand-binding domain, but lacks the membrane-spanning and intracellular kinase domains of the full-length membrane bound Flt-1 (mbFlt-1) protein. Thus, sFlt-1 is an endogenous inhibitor of VEGF-A mediated angiogenesis. Synthetic mopholino oligomers directed against splice site targets can modulate splice variant expression. We hypothesize that morpholino-induced upregulation of sFlt-1 will suppress angiogenesis in clinically relevant models of macular degeneration and breast cancer.
Methods And Findings: In vivo morpholino constructs were designed to target murine exon/intron 13 junction of the Flt-1 transcript denoted VEGFR1_MOe13; standard nonspecific morpholino was used as control. After nucleofection of endothelial and breast adenocarcinoma cell lines, total RNA was extracted and real-time RT-PCR performed for sFlt-1 and mbFlt-1. Intravitreal injections of VEGFR1_MOe13 or control were done in a model of laser-induced choroidal neovascularization and intratumoral injections were performed in MBA-MD-231 xenografts in nude mice. VEGFR1_MOe13 elevated sFlt-1 mRNA expression and suppressed mbFlt-1 mRNA expression in vitro in multiple cellular backgrounds (p<0.001). VEGFR1_MOe13 also elevated sFlt/mbFlt-1 ratio in vivo after laser choroidal injury 5.5 fold (p<0.001) and suppressed laser-induced CNV by 50% (p = 0.0179). This latter effect was reversed by RNAi of sFlt-1, confirming specificity of morpholino activity through up-regulation of sFlt-1. In the xenograft model, VEGFR1_MOe13 regressed tumor volume by 88.9%, increased sFlt-1 mRNA expression, and reduced vascular density by 50% relative to control morpholino treatment (p<0.05).
Conclusions: Morpholino oligomers targeting the VEGFR1 mRNA exon/intron 13 junction promote production of soluble FLT-1 over membrane bound FLT-1, resulting in suppression of lesional volume in laser induced CNV and breast adenocarcinoma. Thus, morpholino manipulation of alternative splicing offers translational potential for therapy of angiogenic disorders.
Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications.
Wazan L, Widhibrata A, Liu G Angiogenesis. 2024; 27(4):641-661.
PMID: 39207600 DOI: 10.1007/s10456-024-09942-8.
Jia J, Jiang W, Luo X, Li R, Zhao Y, Tian G World J Diabetes. 2021; 12(4):480-498.
PMID: 33889292 PMC: 8040075. DOI: 10.4239/wjd.v12.i4.480.
Alternative splicing in endothelial cells: novel therapeutic opportunities in cancer angiogenesis.
Di Matteo A, Belloni E, Pradella D, Cappelletto A, Volf N, Zacchigna S J Exp Clin Cancer Res. 2020; 39(1):275.
PMID: 33287867 PMC: 7720527. DOI: 10.1186/s13046-020-01753-1.
Faycal C, Brambilla E, Agorreta J, Lepeltier N, Jacquet T, Lemaitre N Br J Cancer. 2018; 118(12):1596-1608.
PMID: 29795310 PMC: 6008445. DOI: 10.1038/s41416-018-0128-4.
GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer.
Checa-Rojas A, Delgadillo-Silva L, Del Castillo Velasco-Herrera M, Andrade-Dominguez A, Gil J, Santillan O Oncotarget. 2018; 9(31):21696-21714.
PMID: 29774096 PMC: 5955133. DOI: 10.18632/oncotarget.24796.